ArticleJACC. Case reports2026
Apolipoprotein A-IV Cardiac Amyloidosis Presenting as Massive Ventricular Wall Thickening Mimicking Hypertrophic Cardiomyopathy.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApolipoprotein A-IV amyloidosis (AApoAIV) is a rare systemic amyloidosis that can involve the heart and mimic hypertrophic cardiomyopathy. CASE SUMMARY: A 64-year-old woman with presumed hypertrophic cardiomyopathy presented with dyspnea. Imaging showed severe left ventricular wall thickening, outflow tract obstruction, and systolic anterior motion of the mitral valve. Multimodality evaluation suggested infiltrative cardiomyopathy including diffuse late gadolinium enhancement, abnormal nulling, elevated T1 on cardiac magnetic resonance, and an apical-sparing strain pattern on echocardiography. Technetium-99m pyrophosphate scintigraphy demonstrated no myocardial uptake. Endomyocardial biopsy confirmed AApoAIV deposition. DISCUSSION: AApoAIV cardiac amyloidosis may present with massive left ventricular wall thickening. Discordant noninvasive testing may occur, and endomyocardial biopsy remains essential for diagnosis. TAKE-HOME MESSAGES: AApoAIV cardiac amyloidosis is a rare infiltrative cardiomyopathy that may mimic hypertrophic cardiomyopathy and follow an indolent course, allowing myocardial infiltration over years. Negative technetium-99m pyrophosphate scintigraphy does not exclude amyloidosis, particularly in non-transthyretin amyloid subtypes like AApoAIV, and tissue diagnosis is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.